Skip to main content

Select Drug Profiles

Conference Highlights ASH
More Transplants Made Possible Through Haploidentical Donors
Caroline Helwick
Read More
Conference Highlights ASH
Hospital Readmission After Stem-Cell Transplant Decreases Survival
Wayne Kuznar
Read More
Conference Highlights ASH
JAK1/2 Inhibitor Ruxolitinib Improves Survival in High-Risk Myelofibrosis
Wayne Kuznar
Read More
Perspectives
Increasing Emphasis on Costs in the Management of Patients with Hematologic Cancers
Matthew Mitchell, PharmD, MBA, FAMCP
Read More
Lymphoma
Rituximab Maintenance Extends Remission in Follicular Lymphoma, but Overall Survival Unaffected
Caroline Helwick
Read More
Lymphoma
Surveillance Scanning in Transformed Indolent Lymphoma of Limited Clinical Benefit
Wayne Kuznar
Read More
Lymphoma
PI3K Inhibitors Main Focus of Drug Pipeline for Lymphoma
Caroline Helwick
Read More
Promise of Genomic Sequencing for Clinical Decision-Making in Hematopoietic Cancers
Wayne Kuznar
Read More
Multiple Myeloma, Oncology
Myeloma Drug Arsenal Expanding to New Classes
Caroline Helwick
Read More
Multiple Myeloma, Oncology
Lenalidomide Maintenance in Transplant-Eligible Myeloma Population Still Debated
Caroline Helwick
Read More
Page 158 of 244
Results 1571 - 1580 of 2438